Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
The University of Texas Health Science Center, Houston
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
76High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02494713CT.gov Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT00193271CT.gov Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer | — | Completed | — | — | — |
NCT00083005CT.gov Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate | — | Completed | — | — | — |
NCT00165399CT.gov Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | — | Completed | — | — | — |
NCT00132756CT.gov Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | — | Terminated | — | — | — |
NCT00084565CT.gov Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer | — | Withdrawn | — | — | — |
NCT00027859CT.gov Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00055731CT.gov Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse | — | Completed | — | — | — |
NCT00176527CT.gov Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | — | Terminated | — | — | — |
NCT00052845CT.gov Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
Show 29 more trialsShow fewer
NCT00030654CT.gov Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00218205CT.gov A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer | — | Unknown | — | — | — |
NCT00024167CT.gov Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT00151086CT.gov Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00028769CT.gov S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00046826CT.gov Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy | — | Completed | — | — | — |
NCT00025194CT.gov Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer | — | Completed | — | — | — |
NCT00016107CT.gov Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00016913CT.gov Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | — | Completed | — | — | — |
NCT00005847CT.gov Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT01250717CT.gov Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer | — | Completed | — | — | — |
NCT00038246CT.gov Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | — | Completed | — | — | — |
NCT00014352CT.gov Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00193193CT.gov Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | — | Completed | — | — | — |
NCT00038168CT.gov Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma | — | Completed | — | — | — |
NCT00005810CT.gov Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00004054CT.gov Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00004001CT.gov S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00005627CT.gov Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00003614CT.gov Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00151060CT.gov Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate | — | Completed | — | — | — |
NCT00003717CT.gov Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT00003633CT.gov Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | — | Unknown | — | — | — |
NCT00003394CT.gov Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | — | Completed | — | — | — |
NCT00002775CT.gov Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT00003084CT.gov Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00005048CT.gov Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00002855CT.gov Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer | — | Completed | — | — | — |
NCT00002721CT.gov Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Estramustine (this asset) | The University of Texas Health Science Center, Houston | P3 | BB · 70 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Estramustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Adenocarcinoma | — | P2 | B · 63 |
| Prostate Neoplasm | — | P3 | B · 59 |
| Lymphoma | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Estramustine in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/estramustine-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →